Ba Ming-chen, Cui Shu-zhong, Luo Fu-tian, Ouyang Wen-Wei, Tang Yun-Qiang, Wu Yin-Bing, Tang Hong-Sheng
Department of Abdominal Surgery, Affiliated Oncologic Hospital, Guangzhou Medical College, Guangzhou 510095, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2011 Feb;14(2):132-5.
To evaluated the safety and efficacy of hyperthermic intraperitoneal perfusion chemotherapy(HIPC) in the prevention and treatment of pseudomyxoma peritonei (PMP) recurrence after cytoreductive surgery(CRS).
Studies published in English before 2010 on HIPC after CRS for PMP were searched in PubMed database. Each study was carefully evaluated based on pre-determined criteria. Study results were comprehensively displayed in a form. A descriptive systematic review was performed.
A total of 11 studies were included. The median survival time of patients in these studies ranged from 25.6 months to 156 months. The ranges of 1-year, 2-year, 3-year, 5-year, and 10-year survival rates were 72%-100%, 55%-96%, 59%-96%, 52%-96%, and 55%-96%, respectively. The overall complication rate ranged from 2%-15%, and the total perioperative mortality were from 0 to 7%.
HIPC after CRS is effective and safe for patients with PMP.
